A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease

被引:33
作者
McCurdy, Jeffrey D. [1 ,2 ]
Israel, Amanda [1 ]
Hasan, Maryam [1 ]
Weng, Robin [1 ]
Mallick, Ranjeeta [2 ]
Ramsay, Tim [2 ]
Carrier, Marc [2 ,3 ]
机构
[1] Ottawa Hosp, Div Gastroenterol, Ottawa, ON, Canada
[2] Ottawa Hosp, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[3] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada
关键词
MEDICAL PATIENTS; ULCERATIVE-COLITIS; RISK-FACTORS; THROMBOPROPHYLAXIS; PROPHYLAXIS; THROMBOSIS; DURATION; EVENTS; EPIDEMIOLOGY; METAANALYSIS;
D O I
10.1111/apt.15286
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patients with inflammatory bowel disease (IBD) are at increased risk of venous thromboembolism (VTE) during hospitalisation and potentially post-discharge. Aims To determine the incidence and risk factors for post-discharge VTE in IBD patients and create a point of care predictive model to assess VTE risk. Methods Hospitalised IBD patients were identified from our institutional discharge database between 2009 and 2016, and were assessed for VTE by chart review. Risk factors for VTE within 3 months of discharge were determined by univariable and multivariable logistic regression. A point of care model was created using variables from the univariate analysis with P < 0.05, and internally validated by bootstrap methods. Results Sixty-six of 2161 eligible discharges (3%) were associated with VTE within 6 months of hospitalisation. The median time to event was 37 days (range 3-182 days). On multivariable analysis age >45 years (OR 3.76; 95% CI 1.80-7.89) and multiple admissions (OR 2.62; 95% CI 1.34-5.11) were independently associated with VTE risk. Our final model incorporated age >45 years, multiple admissions, intensive care unit admission, length of admission >7 days and central catheter and was able to discriminate between discharges associated with and without VTE (optimism-corrected c-statistic, 0.70; 95% CI 0.58-0.77). By limiting treatment to a high-risk group, extended thromboprophylaxis could be avoided in 92% of discharges with a miss rate of 1.6% (32/1982 discharges). Conclusion Patients with IBD remain at risk of VTE after hospital discharge. Our model may help clinicians stratify which patients will benefit most from extended thrombophrophylaxis.
引用
收藏
页码:1493 / 1501
页数:9
相关论文
共 50 条
  • [21] Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease
    Lee, Kate E.
    Lim, Francesca
    Colombel, Jean-Frederic
    Hur, Chin
    Faye, Adam S.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (08) : 1169 - 1176
  • [22] Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery
    Papa, Alfredo
    Tursi, Antonio
    Danese, Silvio
    Rapaccini, Gianludovico
    Gasbarrini, Antonio
    Papa, Valerio
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 12
  • [23] Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease Extends beyond Hospitalization
    Bafford, Andrea C.
    Cross, Raymond K.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (11) : 1769 - 1770
  • [24] Venous and arterial thromboembolism in patients with inflammatory bowel diseases
    Stadnicki, Antoni
    Stadnicka, Izabela
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (40) : 6757 - 6774
  • [25] Inflammatory bowel disease and thromboembolism
    Petros Zezos
    Georgios Kouklakis
    Fred Saibil
    World Journal of Gastroenterology, 2014, (38) : 13863 - 13878
  • [26] Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
    Kim, Su Young
    Cho, Yeon Seo
    Kim, Hyun-Soo
    Lee, Jung Kuk
    Kim, Hee Man
    Park, Hong Jun
    Kim, Hyunil
    Kim, Jihoon
    Kang, Dae Ryong
    GUT AND LIVER, 2021, : 555 - 566
  • [27] Inflammatory Bowel Disease Therapy and Venous Thromboembolism
    Thomas Lambin
    Adam S. Faye
    Jean-Frédéric Colombel
    Current Treatment Options in Gastroenterology, 2020, 18 (3) : 462 - 475
  • [28] Inflammatory Bowel Disease Is a Risk Factor for Recurrent Venous Thromboembolism
    Novacek, Gottfried
    Weltermann, Ansgar
    Sobala, Anna
    Tilg, Herbert
    Petritsch, Wolfgang
    Reinisch, Walter
    Mayer, Andreas
    Haas, Thomas
    Kaser, Arthur
    Feichtenschlager, Thomas
    Fuchssteiner, Harry
    Knoflach, Peter
    Vogelsang, Harald
    Miehsler, Wolfgang
    Platzer, Reingard
    Tillinger, Wolfgang
    Jaritz, Bernhard
    Schmid, Alfons
    Blaha, Benedikt
    Dejaco, Clemens
    Eichinger, Sabine
    GASTROENTEROLOGY, 2010, 139 (03) : 779 - U114
  • [29] Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease
    Fujiya, Mikihiro
    Kawaguchi, Tsutomu
    Arai, Shoko
    Isogawa, Naoki
    Hiro, Shintaro
    Matsumoto, Fumihiro
    Yamaguchi, Satoshi
    Yoshii, Noritoshi
    Nakamura, Mashio
    Matsuoka, Katsuyoshi
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (11) : 5195 - 5205
  • [30] Controversies in Venous Thromboembolism Risk Assessment in Inflammatory Bowel Disease: A Narrative Review
    Sharma, Nikhil
    Tewatia, Pavit
    Harvey, Philip R.
    Kumar, Aditi
    DIAGNOSTICS, 2024, 14 (19)